Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Quantumup
Quantumup Sep. 14 at 10:18 AM
Raymond James⬆️ $SRRK's PT to $72 vs $65 and reit'd Strong Buy ~ sees rapid ISEMBYLD US uptake—ests. $2.2B revenue on 50% penetration in 2035: $BIIB - IONS $RHHBY - PTCT NVS Truist⬆️Scholar Rock's PT to $76 vs $55 and reit'd Buy ~ Based on its due-diligence including prior KOL checks, they continue to believe in broad uptake of the drug in combination with SMN2. Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2099442394156388539?s=20
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 11 at 2:30 PM
$IFRX Awesome to see short 12.3m this morning. A 32% increase from just 30 days ago (+3m shares). Based on last 10 trading days volume —-it wld take 19.3 days to cover 12.3m The funds who bought did so for a reason —-and around current pricing + / -$2. They buy for 10-20x They bought because $AMGN has an FDA approved drug that used fraud in its datasets. Already removed from UK and Europe, it’s eventually gonna be removed in “litigation friendly” US. The longer it takes, the better for Inflarx. A proven backup is in the wings. #LiverTox optics can’t look great for Amgen. $BIIB $RHHBY $PFE gotta be looking.
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:22 PM
BMO Capital reiterated $SRRK Outperform-$76 and said -- Physician Expert Survey Supports Broad Uptake of Apitegromab in SMA $RHHBY $NVS BIIB - IONS PTCT LLY NVO BMY REGN BMO Capital added—Proprietary physician survey points to broad potential usage of Scholar Rock's apitegromab on top of SMN-directed therapy for patients with spinal muscular atrophy (SMA). Key takeaways from neurologist survey (n = 15) 1) Broad potential eligibility, with 62% of SMN-treated patients viewed as candidates; 2) strong physician interest, with 73% of surveyed physicians planning to prescribe within six months; and 3) adoption driven primarily by motor-function improvement and clean safety. These results support our bullish view of Scholar Rock shares into the September 30, 2026, PDUFA.
0 · Reply
scdtrader213
scdtrader213 Sep. 10 at 2:48 PM
$RHHBY giving it all back
0 · Reply
SniperPro
SniperPro Sep. 9 at 4:32 PM
$NVS $LXRX $BMY $MRK $RHHBY 🚨 ATTENTION CEOs & BIOTECH LEADERS! 🚨 LOOKING TO EXPAND YOUR ONCOLOGY AI DATA CAPABILITIES? 🧬🤖 $LXRX HAS A MASSIVE, DECADES-LONG GENOMIC DATASET THAT COULD OFFER A POWERFUL OPPORTUNITY FOR AI-DRIVEN ONCOLOGY RESEARCH. IF YOU’RE LOOKING TO PARTNER, THIS IS ONE TO WATCH. 🤝🔥 $LXRX is evaluating AI to unlock the potential of its massive Genome 5,000 database, built from decades of structured and unstructured genomic data. 🧬🤖 - Lexicon's CEO Mike Exton 09/09/2026 The goal: automate data searches and rapidly uncover new opportunities, including in oncology—a space the company has barely explored. 🚀 Potentially a very interesting asset for future oncology partnerships. 🤝 ....
0 · Reply
Woodman7
Woodman7 Sep. 9 at 2:47 PM
$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 9 at 10:39 AM
$MRK $BMY $ABBV $RHHBY $NVS Under the radar Midcap Oncology Biotech TLK has PDUFA Date on the day after tomorrow (Friday). If Approved, TLK could go parabolic but no promises.
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 8 at 1:04 PM
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd
0 · Reply
BillyBig
BillyBig Sep. 5 at 1:17 PM
$RHHBY https://www.dailymail.com/news/article-16106001/Healthy-middle-aged-Britons-offered-Alzheimers-drug-trial-aiming-prevent-dementia.html
0 · Reply
imatisse
imatisse Sep. 2 at 10:48 AM
Go for it Roche Genentech! $LCTX $RHHBY #Opregen The #regenerative medicine "Replace and Restore" cellular approach!
0 · Reply
Latest News on RHHBY
No data available.
Quantumup
Quantumup Sep. 14 at 10:18 AM
Raymond James⬆️ $SRRK's PT to $72 vs $65 and reit'd Strong Buy ~ sees rapid ISEMBYLD US uptake—ests. $2.2B revenue on 50% penetration in 2035: $BIIB - IONS $RHHBY - PTCT NVS Truist⬆️Scholar Rock's PT to $76 vs $55 and reit'd Buy ~ Based on its due-diligence including prior KOL checks, they continue to believe in broad uptake of the drug in combination with SMN2. Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2099442394156388539?s=20
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 11 at 2:30 PM
$IFRX Awesome to see short 12.3m this morning. A 32% increase from just 30 days ago (+3m shares). Based on last 10 trading days volume —-it wld take 19.3 days to cover 12.3m The funds who bought did so for a reason —-and around current pricing + / -$2. They buy for 10-20x They bought because $AMGN has an FDA approved drug that used fraud in its datasets. Already removed from UK and Europe, it’s eventually gonna be removed in “litigation friendly” US. The longer it takes, the better for Inflarx. A proven backup is in the wings. #LiverTox optics can’t look great for Amgen. $BIIB $RHHBY $PFE gotta be looking.
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:22 PM
BMO Capital reiterated $SRRK Outperform-$76 and said -- Physician Expert Survey Supports Broad Uptake of Apitegromab in SMA $RHHBY $NVS BIIB - IONS PTCT LLY NVO BMY REGN BMO Capital added—Proprietary physician survey points to broad potential usage of Scholar Rock's apitegromab on top of SMN-directed therapy for patients with spinal muscular atrophy (SMA). Key takeaways from neurologist survey (n = 15) 1) Broad potential eligibility, with 62% of SMN-treated patients viewed as candidates; 2) strong physician interest, with 73% of surveyed physicians planning to prescribe within six months; and 3) adoption driven primarily by motor-function improvement and clean safety. These results support our bullish view of Scholar Rock shares into the September 30, 2026, PDUFA.
0 · Reply
scdtrader213
scdtrader213 Sep. 10 at 2:48 PM
$RHHBY giving it all back
0 · Reply
SniperPro
SniperPro Sep. 9 at 4:32 PM
$NVS $LXRX $BMY $MRK $RHHBY 🚨 ATTENTION CEOs & BIOTECH LEADERS! 🚨 LOOKING TO EXPAND YOUR ONCOLOGY AI DATA CAPABILITIES? 🧬🤖 $LXRX HAS A MASSIVE, DECADES-LONG GENOMIC DATASET THAT COULD OFFER A POWERFUL OPPORTUNITY FOR AI-DRIVEN ONCOLOGY RESEARCH. IF YOU’RE LOOKING TO PARTNER, THIS IS ONE TO WATCH. 🤝🔥 $LXRX is evaluating AI to unlock the potential of its massive Genome 5,000 database, built from decades of structured and unstructured genomic data. 🧬🤖 - Lexicon's CEO Mike Exton 09/09/2026 The goal: automate data searches and rapidly uncover new opportunities, including in oncology—a space the company has barely explored. 🚀 Potentially a very interesting asset for future oncology partnerships. 🤝 ....
0 · Reply
Woodman7
Woodman7 Sep. 9 at 2:47 PM
$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 9 at 10:39 AM
$MRK $BMY $ABBV $RHHBY $NVS Under the radar Midcap Oncology Biotech TLK has PDUFA Date on the day after tomorrow (Friday). If Approved, TLK could go parabolic but no promises.
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 8 at 1:04 PM
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd
0 · Reply
BillyBig
BillyBig Sep. 5 at 1:17 PM
$RHHBY https://www.dailymail.com/news/article-16106001/Healthy-middle-aged-Britons-offered-Alzheimers-drug-trial-aiming-prevent-dementia.html
0 · Reply
imatisse
imatisse Sep. 2 at 10:48 AM
Go for it Roche Genentech! $LCTX $RHHBY #Opregen The #regenerative medicine "Replace and Restore" cellular approach!
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 1 at 6:32 PM
$IFRX Hot off the press is Oppenheimer today w reiterattion of $9 target on removal of $AMGN Tavenos by MHRA (UK). Heads I win, Tails you lose mentality cited: “US withdrawal process is ongoing. Amgen filed its hearing response to the FDA's proposed Taveneos withdrawal on July 23. ***** The contested process is expected to extend well into 2027, but IFRX remains advantaged under either outcome: withdrawal creates a greenfield, while continued availability lets Amgen build the market for a potentially better-tolerated oral C5aR inhibitor in izicopan.**** How long before Tavneos could be removed from the US market? There is no direct precedent; Tavneos is the first fully approved drug facing withdrawal over pivotal data manipulation.” $BIIB $PFE $RHHBY
1 · Reply
Ablidy
Ablidy Sep. 1 at 1:14 PM
$LCTX $RHHBY
0 · Reply
Ablidy
Ablidy Sep. 1 at 1:12 PM
$LCTX $RHHBY
0 · Reply
TW_Research
TW_Research Sep. 1 at 12:09 PM
$KZIA Lots of news out today along with a conference call going on now. The news here is beyond exciting when you consider this is clearly the best in class PI3K/MTOR inhibitor and has just now opened up new indications. This will soon enough be a multi-billion dollar drug and the current market cap (fully diluted) is under $300M. REalize that when I say fully diluted, that would mean they have $140M of cash if the warrants are exercised. Fully funded and off to the races. Thanks for sharing this drug with us $RHHBY . Coming after you $CELC .
2 · Reply
MQuick
MQuick Sep. 1 at 11:45 AM
$GANX its september and its time BP $RHHBY $SNY $MRK
0 · Reply
GoPatzGo123
GoPatzGo123 Aug. 31 at 7:40 PM
$ONCY lol all the cancer biotech companies getting bought up except us. C'mom two to 3 billion dollars is pocket change for companies like $MRCY $PFE $RHHBY What are ya waiting for???
2 · Reply
imatisse
imatisse Aug. 31 at 11:32 AM
Go for it Roche Genentech! $LCTX $RHHBY #Opregen
0 · Reply
imatisse
imatisse Aug. 28 at 6:42 PM
$LCTX - - #Opregen $RHHBY AlloSCOPE isn’t one secret trick — it’s cell line + differentiation protocol + scale-up process + validation data, all stacked together. Each piece has to be reverse-engineered separately, and none of it is public. That’s what makes @LineageCell’s stem cell platform hard to copy.
1 · Reply
imatisse
imatisse Aug. 27 at 12:30 PM
Go for it Roche Genentech! $LCTX $RHHBY #Opregen
0 · Reply
Tom2772
Tom2772 Aug. 26 at 2:57 PM
$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice
0 · Reply